Cargando…

The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms

Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Semo, Dilvin, Obergassel, Julius, Dorenkamp, Marc, Hemling, Pia, Strutz, Jasmin, Hiden, Ursula, Müller, Nicolle, Müller, Ulrich Alfons, Zulfikar, Sajan Ahmad, Godfrey, Rinesh, Waltenberger, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962711/
https://www.ncbi.nlm.nih.gov/pubmed/36835891
http://dx.doi.org/10.3390/jcm12041356
_version_ 1784896073482895360
author Semo, Dilvin
Obergassel, Julius
Dorenkamp, Marc
Hemling, Pia
Strutz, Jasmin
Hiden, Ursula
Müller, Nicolle
Müller, Ulrich Alfons
Zulfikar, Sajan Ahmad
Godfrey, Rinesh
Waltenberger, Johannes
author_facet Semo, Dilvin
Obergassel, Julius
Dorenkamp, Marc
Hemling, Pia
Strutz, Jasmin
Hiden, Ursula
Müller, Nicolle
Müller, Ulrich Alfons
Zulfikar, Sajan Ahmad
Godfrey, Rinesh
Waltenberger, Johannes
author_sort Semo, Dilvin
collection PubMed
description Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG trial). Since SGLT-2 is known to be expressed on cells other than the kidney cells, we investigated the potential ability of empagliflozin to regulate glucose transport and alleviate hyperglycaemia-induced dysfunction of these cells. Methods: Primary human monocytes were isolated from the peripheral blood of T2DM patients and healthy individuals. Primary human umbilical vein endothelial cells (HUVECs) and primary human coronary artery endothelial cells (HCAECs), and fetoplacental endothelial cells (HPECs) were used as the EC model cells. Cells were exposed to hyperglycaemic conditions in vitro in 40 ng/mL or 100 ng/mL empagliflozin. The expression levels of the relevant molecules were analysed by RT-qPCR and confirmed by FACS. Glucose uptake assays were carried out with a fluorescent derivative of glucose, 2-NBDG. Reactive oxygen species (ROS) accumulation was measured using the H(2)DFFDA method. Monocyte and endothelial cell chemotaxis were measured using modified Boyden chamber assays. Results: Both primary human monocytes and endothelial cells express SGLT-2. Hyperglycaemic conditions did not significantly alter the SGLT-2 levels in monocytes and ECs in vitro or in T2DM conditions. Glucose uptake assays carried out in the presence of GLUT inhibitors revealed that SGLT-2 inhibition very mildly, but not significantly, suppressed glucose uptake by monocytes and endothelial cells. However, we detected the significant suppression of hyperglycaemia-induced ROS accumulation in monocytes and ECs when empagliflozin was used to inhibit SGLT-2 function. Hyperglycaemic monocytes and endothelial cells readily exhibited impaired chemotaxis behaviour. The co-treatment with empagliflozin reversed the PlGF-1 resistance phenotype of hyperglycaemic monocytes. Similarly, the blunted VEGF-A responses of hyperglycaemic ECs were also restored by empagliflozin, which could be attributed to the restoration of the VEGFR-2 receptor levels on the EC surface. The induction of oxidative stress completely recapitulated most of the aberrant phenotypes exhibited by hyperglycaemic monocytes and endothelial cells, and a general antioxidant N-acetyl-L-cysteine (NAC) was able to mimic the effects of empagliflozin. Conclusions: This study provides data indicating the beneficial role of empagliflozin in reversing hyperglycaemia-induced vascular cell dysfunction. Even though both monocytes and endothelial cells express functional SGLT-2, SGLT-2 is not the primary glucose transporter in these cells. Therefore, it seems likely that empagliflozin does not directly prevent hyperglycaemia-mediated enhanced glucotoxicity in these cells by inhibiting glucose uptake. We identified the reduction of oxidative stress by empagliflozin as a primary reason for the improved function of monocytes and endothelial cells in hyperglycaemic conditions. In conclusion, empagliflozin reverses vascular cell dysfunction independent of glucose transport but could partially contribute to its beneficial cardiovascular effects.
format Online
Article
Text
id pubmed-9962711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99627112023-02-26 The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms Semo, Dilvin Obergassel, Julius Dorenkamp, Marc Hemling, Pia Strutz, Jasmin Hiden, Ursula Müller, Nicolle Müller, Ulrich Alfons Zulfikar, Sajan Ahmad Godfrey, Rinesh Waltenberger, Johannes J Clin Med Article Purpose: Hyperglycaemia-induced oxidative stress and inflammation contribute to vascular cell dysfunction and subsequent cardiovascular events in T2DM. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin significantly improves cardiovascular mortality in T2DM patients (EMPA-REG trial). Since SGLT-2 is known to be expressed on cells other than the kidney cells, we investigated the potential ability of empagliflozin to regulate glucose transport and alleviate hyperglycaemia-induced dysfunction of these cells. Methods: Primary human monocytes were isolated from the peripheral blood of T2DM patients and healthy individuals. Primary human umbilical vein endothelial cells (HUVECs) and primary human coronary artery endothelial cells (HCAECs), and fetoplacental endothelial cells (HPECs) were used as the EC model cells. Cells were exposed to hyperglycaemic conditions in vitro in 40 ng/mL or 100 ng/mL empagliflozin. The expression levels of the relevant molecules were analysed by RT-qPCR and confirmed by FACS. Glucose uptake assays were carried out with a fluorescent derivative of glucose, 2-NBDG. Reactive oxygen species (ROS) accumulation was measured using the H(2)DFFDA method. Monocyte and endothelial cell chemotaxis were measured using modified Boyden chamber assays. Results: Both primary human monocytes and endothelial cells express SGLT-2. Hyperglycaemic conditions did not significantly alter the SGLT-2 levels in monocytes and ECs in vitro or in T2DM conditions. Glucose uptake assays carried out in the presence of GLUT inhibitors revealed that SGLT-2 inhibition very mildly, but not significantly, suppressed glucose uptake by monocytes and endothelial cells. However, we detected the significant suppression of hyperglycaemia-induced ROS accumulation in monocytes and ECs when empagliflozin was used to inhibit SGLT-2 function. Hyperglycaemic monocytes and endothelial cells readily exhibited impaired chemotaxis behaviour. The co-treatment with empagliflozin reversed the PlGF-1 resistance phenotype of hyperglycaemic monocytes. Similarly, the blunted VEGF-A responses of hyperglycaemic ECs were also restored by empagliflozin, which could be attributed to the restoration of the VEGFR-2 receptor levels on the EC surface. The induction of oxidative stress completely recapitulated most of the aberrant phenotypes exhibited by hyperglycaemic monocytes and endothelial cells, and a general antioxidant N-acetyl-L-cysteine (NAC) was able to mimic the effects of empagliflozin. Conclusions: This study provides data indicating the beneficial role of empagliflozin in reversing hyperglycaemia-induced vascular cell dysfunction. Even though both monocytes and endothelial cells express functional SGLT-2, SGLT-2 is not the primary glucose transporter in these cells. Therefore, it seems likely that empagliflozin does not directly prevent hyperglycaemia-mediated enhanced glucotoxicity in these cells by inhibiting glucose uptake. We identified the reduction of oxidative stress by empagliflozin as a primary reason for the improved function of monocytes and endothelial cells in hyperglycaemic conditions. In conclusion, empagliflozin reverses vascular cell dysfunction independent of glucose transport but could partially contribute to its beneficial cardiovascular effects. MDPI 2023-02-08 /pmc/articles/PMC9962711/ /pubmed/36835891 http://dx.doi.org/10.3390/jcm12041356 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Semo, Dilvin
Obergassel, Julius
Dorenkamp, Marc
Hemling, Pia
Strutz, Jasmin
Hiden, Ursula
Müller, Nicolle
Müller, Ulrich Alfons
Zulfikar, Sajan Ahmad
Godfrey, Rinesh
Waltenberger, Johannes
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
title The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
title_full The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
title_fullStr The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
title_full_unstemmed The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
title_short The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
title_sort sodium-glucose co-transporter 2 (sglt2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose transport-independent but redox-dependent mechanisms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962711/
https://www.ncbi.nlm.nih.gov/pubmed/36835891
http://dx.doi.org/10.3390/jcm12041356
work_keys_str_mv AT semodilvin thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT obergasseljulius thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT dorenkampmarc thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT hemlingpia thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT strutzjasmin thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT hidenursula thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT mullernicolle thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT mullerulrichalfons thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT zulfikarsajanahmad thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT godfreyrinesh thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT waltenbergerjohannes thesodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT semodilvin sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT obergasseljulius sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT dorenkampmarc sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT hemlingpia sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT strutzjasmin sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT hidenursula sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT mullernicolle sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT mullerulrichalfons sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT zulfikarsajanahmad sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT godfreyrinesh sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms
AT waltenbergerjohannes sodiumglucosecotransporter2sglt2inhibitorempagliflozinreverseshyperglycemiainducedmonocyteandendothelialdysfunctionprimarilythroughglucosetransportindependentbutredoxdependentmechanisms